Key facts
- Notable investors include Accelerating FemTech, Alma Angels, Fortuna Fellowship, Lifted Ventures, Mint Ventures (UK).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for MyBliss
- ·The full record, as it builds
Funding rounds
No funding rounds for MyBliss are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MyBliss
Operator of intimate wellness tool intended for safe and comfortable sexual health purposes. The company provides products formulated to protect vaginal balance, including ultra-thin options free from spermicide, vegan-certified materials, pH-balanced lubricants, and dermatologist-tested balms, supported by research into microbiome safety and gynecologist endorsements, enabling women and couples to reduce irritation, maintain long-term intimate health, access reliable alternatives to conventional offerings, and ensure that sexual wellbeing is prioritized through evidence-based design and accessible distribution across the United Kingdom and wider European markets.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 3
- Website
- my-bliss.co.uk/
- Ownership
- Privately Held (backing)
MyBliss doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MyBliss shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MyBliss in its N-PORT filings yet. We sweep new filings monthly.